The Drug Manufacturers - General industry is part of the Healthcare sector. It holds 67 US-listed stocks. Their average AI MoonshotScore is 68 out of 100. The top 3 names are LLY, BMY, JNJ.
Healthcare
67 Stocks
Drug Manufacturers - General Stocks
Complete list of 67 Drug Manufacturers - General industry stocks with AI-powered MoonshotScore analysis, market-hours price data, and provider-sourced market insights. Part of the Healthcare sector.
▲
Advancing:
14
●
Avg Score:
68
■
Companies:
67
Drug Manufacturers - General Industry Overview
The Drug Manufacturers - General industry, part of the Healthcare sector, comprises 67 publicly traded companies with a combined market capitalization of $7.0T. This includes 13 mega-cap companies (over $200B), reflecting the industry's significant weight in global markets.
Today's market sentiment for Drug Manufacturers - General stocks is Bearish, with 14 stocks advancing and 30 declining. The average price movement across the industry is +61412.06%.
The average AI MoonshotScore across Drug Manufacturers - General stocks is 68/100. MoonshotScore V2 rates eligible US-listed companies from 0 to 100 against their sector peers on five pillars: Business Quality (weight 26), Financial Safety (weight 20), Valuation (weight 18), Growth Durability (weight 16) and Momentum (weight 12). It reads no news-sentiment or analyst data, and it is not a probability of future returns.
Total Market Cap
$7.0T
Median Market Cap
$14.7B
Avg MoonshotScore
68
Top MoonshotScore
97
Advancing Today
14
Total Companies
67
How Are Drug Manufacturers - General Stocks Distributed by Market Cap?
How Drug Manufacturers - General companies are distributed across market capitalization tiers.
Mega Cap
$200B+ · 13 stocks
Large Cap
$10B–$200B · 24 stocks
Mid Cap
$2B–$10B · 14 stocks
Small Cap
Under $2B · 14 stocks
Frequently Asked Questions
How many stocks are in the Drug Manufacturers - General industry?
There are currently 67 listings classified under the Drug Manufacturers - General industry within the Healthcare sector. The tracked companies carry a combined market capitalization of $7.0T, with 14 advancing and 30 declining in today's trading.
Which Drug Manufacturers - General stocks rank highest by MoonshotScore?
Based on our AI MoonshotScore analysis, the top-rated Drug Manufacturers - General stocks are LLY, BMY, JNJ. Always conduct your own research before investing.
What are the largest Drug Manufacturers - General companies by market cap?
The largest Drug Manufacturers - General companies by market capitalization are LLY ($1.08T), BMYMP ($814.59B), JNJ ($617.01B). Across the tracked list, the median market capitalization is $14.7B — a gauge of how top-heavy the industry is beyond its largest names.
What is the average MoonshotScore for Drug Manufacturers - General stocks?
The current average MoonshotScore for the Drug Manufacturers - General industry is 68/100. The strongest current score in the industry is 97/100. MoonshotScore V2 rates eligible US-listed companies from 0 to 100 against their sector peers on five pillars: Business Quality (weight 26), Financial Safety (weight 20), Valuation (weight 18), Growth Durability (weight 16) and Momentum (weight 12). It reads no news-sentiment or analyst data, and it is not a probability of future returns.
How does the Drug Manufacturers - General industry perform compared to the overall market?
Drug Manufacturers - General stocks are tracked against broader market benchmarks. You can compare sector and industry performance on our Market Sectors dashboard.
Our Analysis Methodology
Stock Expert AI rates eligible U.S.-listed companies with the MoonshotScore, a proprietary 0–100 composite rating. V2 is the only current model: eligible companies are scored against their sector peers across five pillars — business quality, financial safety, valuation, growth durability, and momentum. MoonshotScore V2 covers eligible common stocks and ADRs on NASDAQ, NYSE and AMEX. OTC listings are outside the scheduled universe; funds, ETFs, warrants, units, SPACs, preferreds, and notes carry no MoonshotScore.
MoonshotScore V2 rates eligible US-listed companies from 0 to 100 against their sector peers on five pillars: Business Quality (weight 26), Financial Safety (weight 20), Valuation (weight 18), Growth Durability (weight 16) and Momentum (weight 12). It reads no news-sentiment or analyst data, and it is not a probability of future returns.
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. Each price is the last quote we recorded, shown with the trading session it belongs to. Pages are served from a cache, so the copy you are reading can lag that quote. Each quote is a provider snapshot, not an exchange feed.
Sector names are the familiar eleven, but the classification itself is our data provider's, not GICS, and departs from it in places — mortgage REITs, education and packaging are filed the way GICS files them; the rest follow the provider. Companies are assigned to one sector and to one of 50+ industries by their primary revenue source.
Explore More
Healthcare Sector →
View all industries and stocks in the Healthcare sector.
All Industries →
Browse all industries across every sector.
All Sectors →
Compare all 11 sectors by size, performance, and AI scores.
Stock Screener →
Filter Drug Manufacturers - General stocks by market cap, MoonshotScore, and more.
Discover →
Search for any stock by ticker, company name, or keyword.
Data is provided for informational purposes only and should not be considered investment advice. Stock prices, market capitalizations, and MoonshotScores are updated throughout the trading day. Past performance does not guarantee future results. Always consult with a qualified financial advisor before making investment decisions.
Which stocks are in the Drug Manufacturers - General industry?
1–67 of 67 shown| Stock | Price | Change | Volume | Market Cap | MoonshotScore | Sector |
|---|---|---|---|---|---|---|
|
LLY
Eli Lilly and Company
|
$1142.85 | -0.61% | 2.02M | $1.08T | 97 | Healthcare |
|
BMY
Bristol-Myers Squibb Company
|
$61.15 | -0.50% | 9.64M | $124.91B | 91 | Healthcare |
|
JNJ
Johnson & Johnson
|
$256.03 | -1.02% | 10.18M | $617.01B | 90 | Healthcare |
|
GSK
GSK plc
|
$47.03 | -0.32% | 5.35M | $94.22B | 88 | Healthcare |
|
AMGN
Amgen Inc.
|
$403.04 | -1.04% | 3.51M | $217.52B | 85 | Healthcare |
|
AZN
AstraZeneca PLC
|
$156.90 | -0.51% | 2.64M | $243.33B | 85 | Healthcare |
|
NVS
Novartis AG
|
$141.00 | -0.04% | 2.14M | $268.00B | 84 | Healthcare |
|
SNY
Sanofi
|
$39.92 | -1.84% | 4.34M | $95.86B | 83 | Healthcare |
|
ABBV
AbbVie Inc.
|
$262.82 | +1.11% | 5.54M | $464.35B | 78 | Healthcare |
|
MRK
Merck & Co., Inc.
|
$144.30 | +0.34% | 9.16M | $356.40B | 75 | Healthcare |
|
PFE
Pfizer Inc.
|
$27.80 | -1.14% | 34.91M | $158.44B | 68 | Healthcare |
|
BIIB
Biogen Inc.
|
$219.88 | -1.32% | 780.4K | $32.49B | 67 | Healthcare |
|
GRFS
Grifols, S.A.
|
$7.31 | +0.14% | 390.4K | $6.18B | 66 | Healthcare |
|
GILD
Gilead Sciences, Inc.
|
$144.74 | -1.87% | 5.04M | $179.47B | 64 | Healthcare |
|
MIRA
MIRA Pharmaceuticals, Inc.
|
$0.73 | +0.98% | 156.9K | $30.68M | 47 | Healthcare |
|
SRXH
SRx Health Solutions Inc.
|
$1.61 | +0.00% | 473.4K | $15.84M | 41 | Healthcare |
|
OGN
Organon & Co.
|
$13.72 | +0.07% | 1.92M | $3.60B | 37 | Healthcare |
|
SCLX
Scilex Holding Company
|
$4.06 | -7.73% | 107.7K | $28.56M | 19 | Healthcare |
|
CTOR
Citius Oncology, Inc.
|
$0.95 | -3.06% | 208.4K | $88.33M | 18 | Healthcare |
|
ALPMF
Astellas Pharma Inc.
|
$14.37 | -2.06% | 341 | $25.74B | — | Healthcare |
|
ALPMY
Astellas Pharma Inc.
|
$14.32 | -0.83% | 17.1K | $25.68B | — | Healthcare |
|
AZNCF
AstraZeneca PLC
|
$189.90 | -1.35% | 1.43M | $294.40B | — | Healthcare |
|
BAYRY
Bayer AG
|
$12.64 | -0.71% | 25.3K | $49.67B | — | Healthcare |
|
BDSIW
BioDelivery Sciences Intl, Inc. Wrrt
|
$0.04 | -25.00% | 552.1K | 0 | — | Healthcare |
|
BMYMP
Bristol-Myers Squibb Company PFD CONV 2
|
$400.00 | -57.46% | 13 | $814.59B | — | Healthcare |
|
CELG-RI
Bristol-Myers Squibb Company Ce
|
$0.13 | +17.45% | 5.5K | $263.92M | — | Healthcare |
|
CHGCF
Chugai Pharmaceutical Co., Ltd.
|
$38.27 | +1.13% | 300 | $62.98B | — | Healthcare |
|
CHGCY
Chugai Pharmaceutical Co., Ltd.
|
$19.08 | -1.29% | 14.3K | $62.80B | — | Healthcare |
|
CHJTF
CSPC Pharmaceutical Group Limited
|
$1.11 | +0.00% | 2.0K | $12.66B | — | Healthcare |
|
CRXT
Clarus Therapeutics Holdings, Inc.
|
$0.05 | -31.16% | 2.74M | 0 | — | Healthcare |
|
CRXTQ
Clarus Therapeutics Holdings, Inc.
|
$0.00 | +0.00% | 38.3K | $72,829 | — | Healthcare |
|
CSPCY
CSPC Pharmaceutical Group Limited
|
$5.10 | -2.11% | 3.2K | $14.69B | — | Healthcare |
|
DPHAY
Dechra Pharmaceuticals PLC
|
$98.00 | +1.98% | 100 | $5.58B | — | Healthcare |
|
DSKYF
Daiichi Sankyo Company, Limited
|
$17.60 | +0.00% | 5 | $32.03B | — | Healthcare |
|
DSNKY
Daiichi Sankyo Company, Limited
|
$17.38 | +0.40% | 1.7K | $31.64B | — | Healthcare |
|
GIFLF
Grifols, S.A.
|
$11.13 | +0.00% | 5.8K | $7.57B | — | Healthcare |
|
GIFOF
Grifols, S.A.
|
$7.08 | +0.00% | 149 | $6.96B | — | Healthcare |
|
GIKLY
Grifols, S.A.
|
$5.55 | +0.00% | 5 | $14.59B | — | Healthcare |
|
GLAXF
GSK plc
|
$22.77 | +0.00% | 150 | $91.24B | — | Healthcare |
|
HAWPF
Haw Par Corporation Limited
|
$10.80 | +0.00% | 200 | $2.39B | — | Healthcare |
|
HAWPY
Haw Par Corporation Limited
|
$53.50 | +0.00% | 7 | $2.96B | — | Healthcare |
|
HZNP
Horizon Therapeutics Public Limited Company
|
$116.30 | +0.00% | 23.92M | $26.60B | — | Healthcare |
|
JCRRF
JCR Pharmaceuticals Co., Ltd.
|
$3.60 | +8.11% | 100 | $439.26M | — | Healthcare |
|
KYKOF
Kyowa Kirin Co., Ltd.
|
$14.05 | -4.49% | 655 | $7.35B | — | Healthcare |
|
LYPHF
Luye Pharma Group Ltd.
|
$0.27 | +0.00% | 2.5K | $1.08B | — | Healthcare |
|
MAYNF
Mayne Pharma Group Limited
|
$2.00 | +0.00% | 1.2K | $162.49M | — | Healthcare |
|
NVSEF
Novartis AG
|
$134.20 | -4.78% | 1.2K | $255.08B | — | Healthcare |
|
OPHLF
Ono Pharmaceutical Co., Ltd.
|
$14.95 | +0.00% | 625 | $7.03B | — | Healthcare |
|
OPHLY
Ono Pharmaceutical Co., Ltd.
|
$4.80 | -0.83% | 11.1K | $6.77B | — | Healthcare |
|
ORINF
Orion Oyj
|
$92.05 | +0.00% | 100 | $12.97B | — | Healthcare |
|
ORINY
Orion Oyj
|
$48.79 | +0.00% | 5 | $27.47B | — | Healthcare |
|
OTSKF
Otsuka Holdings Co., Ltd.
|
$73.16 | +0.00% | 41 | $38.44B | — | Healthcare |
|
OTSKY
Otsuka Holdings Co., Ltd.
|
$36.19 | +0.22% | 5.5K | $38.03B | — | Healthcare |
|
PSYGF
Psyence Group Inc.
|
$0.14 | +9.76% | 100 | $2.25M | — | Healthcare |
|
PTKFF
PT Kalbe Farma Tbk.
|
$0.05 | +0.00% | 10.0K | $2.37B | — | Healthcare |
|
PTKFY
PT Kalbe Farma Tbk.
|
$7.80 | +0.00% | 68 | $8.84M | — | Healthcare |
|
RCDTF
Recordati Industria Chimica e Farmaceutica S.p.A.
|
$58.79 | +0.00% | 100 | $12.04B | — | Healthcare |
|
RHHBF
Roche Holding AG
|
$419.92 | -1.19% | 53 | $334.58B | — | Healthcare |
|
RHHBY
Roche Holding AG
|
$52.25 | -0.19% | 81.8K | $333.07B | — | Healthcare |
|
RHHVF
Roche Holding AG
|
$428.22 | -3.25% | 35 | $295.01B | — | Healthcare |
|
SCLXW
Scilex Holding Company
|
$0.10 | +0.10% | 2.1K | $28.03M | — | Healthcare |
|
SNPHF
Santen Pharmaceutical Co., Ltd.
|
$13.05 | +0.00% | 2.0K | $4.20B | — | Healthcare |
|
SNPHY
Santen Pharmaceutical Co., Ltd.
|
$10.55 | -5.13% | 300 | $3.39B | — | Healthcare |
|
SNYNF
Sanofi
|
$77.98 | -2.95% | 1 | $93.62B | — | Healthcare |
|
TCRG
The Cannaisseur Group, Inc.
|
$0.06 | — | 350 | $1.11M | — | Healthcare |
|
TGRNF
Tong Ren Tang Technologies Co. Ltd.
|
$0.40 | +0.00% | 1.0K | $511.29M | — | Healthcare |
|
VRBCF
Virbac S.A.
|
$383.25 | +0.00% | 1 | $3.21B | — | Healthcare |
Showing 67 of 67 Drug Manufacturers - General stocks
Drug Manufacturers - General & Healthcare Stories
Evidence & Sources
- Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures.
- MoonshotScore V2 rates eligible US-listed companies from 0 to 100 against their sector peers on five pillars: Business Quality (weight 26), Financial Safety (weight 20), Valuation (weight 18), Growth Durability (weight 16) and Momentum (weight 12). It reads no news-sentiment or analyst data, and it is not a probability of future returns.
- Definitions follow standard investing terminology, with key terms explained inline in plain language where useful.
- Each price is the last quote we recorded, shown with the trading session it belongs to. Pages are served from a cache, so the copy you are reading can lag that quote. Each quote is a provider snapshot, not an exchange feed.
- This page is educational and does not constitute investment advice.
- All analysis is generated by AI models and should be verified with independent research.
Prices: 2026-10-02 trading session · Company analysis text: updated 2026-08-03